Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 financial guidance based on slower than antic
(Financial Post, 2025-10-22T05:06:20Z)